TNF and irritable bowel syndrome: Many studies had explored ideal predictors for primary nonresponders in patients with irritable bowel syndrome receiving anti-TNFα therapy (Ben-Horin et al., 2014; Lopetuso et al., 2017; Gole and Potocnik, 2019).